APROBARBITAL

- Everything we could find out about it

Home ] [ Controlled Substances ] [ Depressants ]

Created Apr 2019 | Updated Nov 2020

APROBARBITAL

  • [ALURATE]
  • [ORAMON]
  • [SOMNIFAINE]
  • [ALLONAL]
  • [APROBARBITONE]

5-isopropyl- 5-allylbarbituric acid

DEA CODE 2100: Schedule 3

Aprobarbital is a barbiturate derivative. Aprobarbital have been used for the short-term treatment of insomnia and for routine sedation to relieve anxiety, tension, and apprehension however, barbiturates generally have been replaced by benzodiazepines.

Aprobarbital is a barbiturate derivative synthesized in the 1920s by Ernst Preiswerk. It has sedative, hypnotic and anticonvulsant properties, and was used primarily for the treatment of insomnia. Aprobarbital was never as widely used as more common barbiturate derivatives such as phenobarbital and is now rarely prescribed. This compound belongs to the class of organic compounds known as barbituric acid derivatives.

  • A barbiturate derivative
  • Invented in the 1920s
  • It has sedative, hypnotic and anticonvulsant properties
  • Was used primarily for the treatment of insomnia

Aprobarbital was never as widely used as the more common barbiturate derivatives like phenobarbital. It is now rarely prescribed as it has been replaced by newer drugs with a better safety margin.

  
Deutetrabenazine Interaction with other Drugs - Deutetrabenazine, a vesicular monoamine transporter 2 inhibitor, is used to treat sudden involuntary or repetitive movements (chorea) which is associated with an inherited disease called as ...
Saturday October 23, 2021 - medindia.net

Clinically Significant Drug-Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: Profiling and Comparison of Two Drug Compendia - Further studies should be conducted to create a standard evaluation tool or selection criteria to standardize the definitions and classifications of DDIs among compendia commonly used to identify ...
Tuesday February 27, 2024 - medscape.com

Clinically Significant Drug-Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: Profiling and Comparison of Two Drug Compendia - However, patients receiving oral therapy are at high risk for drug-drug interactions (DDIs). Objective: To create a drug profile for each clinically significant DDI involving selected oral ...
Tuesday January 23, 2024 - medscape.com

  
Depressants | Link to this page

Home ] [ Controlled Substances ] [ Sources ]


· Controlled Substances
· Depressants
· Aprobarbital